"Designing Growth Strategies is in our DNA"
Chronic back pain is pain that persists after a surgery or injury. The common causes of the chronic back pain include arthritis of the spine, spinal stenosis, disc problems, myofascial pain syndrome, and others. The symptoms commonly seen are acute lower back pain. The pain might spread (radiate) to the buttocks, thighs or knees. Depending on the type of the back pain the treatments are recommended and some of the common treatments recommended are Over-the-counter (OTC) pain reliever, muscle relaxants, topical pain relievers, narcotics, and others. According to a research publication by NCBI, in the United States, the lifetime prevalence of back pain is approximately 80%, with a one-year prevalence rate of 15% to 20%.
Current treatment for chronic back pain includes non-surgical treatment with limited rest, pain medication, and a supervised therapy program. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen are prescribed for chronic back pain.
Pharmaceutical companies have focussed on studying and developing new methods for the treatment of chronic back pain. For instance; PF-06372865, which is being studied by Pfizer Inc., is currently in phase-2 clinical trials for the study the treatment of the chronic lower back pain.
To get details on market share, speak to analyst
At present more than 50% of the pipeline candidates for chronic back pain are in phase 2 and phase 3 stages combined. Majority of the studies have been sponsored by pharmaceutical companies.
The report on ‘Chronic Back Pain – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for chronic back pain. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for chronic back pain.
The report on ‘Chronic Back Pain – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm